Article
Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment
2023-12-02
Abstract excerpt
Immune checkpoint therapy has limited efficacy for patients with bone metastatic castrate-resistant prostate cancer (bmCRPC). In this study, we revealed a novel mechanism that may account for the relative resistance of bmCRPC to immune checkpoint therapy. We found that prostate cancer (PCa)-induced bone via endothelial-to-osteoblast (EC-to-OSB) transition causes an ingress of M2-like macrophages, leading to an imm...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f01594e2-abf2-59c7-9c0a-dac55d078aa4
- DOI
- 10.1101/2023.11.30.569496
